Comparing two maintenance drugs for ovarian cancer without DNA repair defects
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This study compares two maintenance drugs (niraparib vs. bevacizumab) for people with advanced ovarian cancer who do not have certain DNA repair issues (BRCA mutation or HRD). It aims to see which drug works better to keep cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with advanced ovarian cancer (stage III or IV) and have had chemotherapy.
- Your cancer should not have a BRCA gene mutation or a positive HRD test (these are DNA repair problems).
- If you had surgery, it must have been after chemotherapy (not as the first treatment).
- You should have already been taking either bevacizumab or niraparib as maintenance therapy after chemotherapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two PARP inhibitors (drugs that help repair DNA damage) combined with bevacizumab (an anti-angiogenic therapy) as maintenance treatment after chemotherapy in patients with advanced ovarian cancer that has a genetic vulnerability called HRD-positive. The goal is to see which combination works better at preventing cancer recurrence.
This trial tests whether the PARP inhibitor niraparib can help keep advanced ovarian cancer from coming back. You may qualify if you have a BRCA mutation or HRD-positive tumor and finished first-line chemotherapy with bevacizumab (Avastin) with good response.
This study looks at how well the drug niraparib works as a maintenance treatment for women with advanced ovarian cancer that responded well to initial platinum-based chemotherapy. It may help keep the cancer from coming back.
This study looks at how well niraparib works as maintenance therapy for women with advanced ovarian, fallopian tube, or primary peritoneal cancer who have already responded to initial chemotherapy. It aims to gather real-world data on the treatment's effectiveness and safety.
This trial tests a combination of two drugs (Senaparib and Bevacizumab) as a first treatment after chemotherapy for women with advanced ovarian cancer that has a specific genetic feature called HRP. The goal is to see if this combination can help keep the cancer from coming back.
This trial studies whether niraparib works better when combined with bevacizumab after chemotherapy and surgery for advanced ovarian, fallopian tube, or peritoneal cancer. If you qualify, you may help researchers find a treatment plan that controls the cancer for longer.
Hear when a new Ovarian Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.